Considering that the estimated 2 year OS of pembrolizumab plus SNK01 in patients with PD‐L1 TPS >50% was 80%, our results suggest that combining pembrolizumab with NK cell infusion could benefit previously treated NSCLC patients. The gene discussed is CD274; the disease is non-small cell lung carcinoma.